Biomarkers as Predictors for Conversion from Mild Cognitive Impairment to Alzheimer-Type Dementia: Implications for Trial Design

Ineke A. van Rossum, Stephanie Vos, Ron Handels, Pieter Jelle Visser*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

78 Citations (Web of Science)
1 Downloads (Pure)
Original languageEnglish
Pages (from-to)881-891
JournalJournal of Alzheimer's Disease
Issue number3
Publication statusPublished - 2010


  • Alzheimer's disease
  • biomarkers
  • blood
  • cerebrospinal fluid
  • cost-benefit
  • decision analysis
  • mild cognitive impairment

Cite this